Interview with André Choulika, President, France Biotech
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
Shire serves as an industry leader in research and treatments of rare and orphan diseases, allowing patients with severe conditions to lead better lives. The company’s deep understanding of patients and their needs enables them to develop and deliver health care in therapeutic areas including, behavioral disorders and gastrointestinal diseases, as well as other symptomatic conditions followed by specialists. Shire upholds an ambition to imagine the future and be at the forefront of health care in creating value for patients, physicians, policymakers, payers and shareholders. Shire France is the French subsidiary of Shire Pharmaceuticals Group plc based in the UK and the US. As the operator of specialty pharmaceuticals and as such, its products are sold by the conventional circuit of distribution: custodians, distributors, pharmaceutical wholesale distributors, pharmacies, care facilities. The French affiliate specializes in therapeutic areas such as hematology, nephrology, central nervous system, gastrointestinal, genetic diseases.
France is a major pharmaceutical market, leader in Europe and number three in the world but it seems in biotechnologies, France lags behind. In your opinion, what has caused this?…
After spending 15 years at the CEA (Nuclear Energy Center), you just accepted an offer to become the General Manager of INSERM at the very moment a political reform is…
July 2008 libre acèss (free access,) for OTC market was implemented – a measure where some selected OTC products were made available over the counter within the pharmacy. Could you…
The creation of AFSSAPS in 1999 was a milestone for the industry as it became the organism which gives authorization to enter a drug into the market. Can you explain…
The US chooses to price its innovative drugs based on a market approach which is very different from the French system. Could you explain how the French model rewards innovative…
What was the idea behind the creation of the « Etats Generaux de l’industrie » (General States of Industries)? What can we expect from them? The main idea is that…
See our Cookie Privacy Policy Here
